Free Trial

Analysts Set Cogent Biosciences, Inc. (NASDAQ:COGT) PT at $16.33

Cogent Biosciences logo with Medical background

Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eleven brokerages that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $18.00.

A number of analysts recently commented on COGT shares. Jefferies Financial Group boosted their target price on Cogent Biosciences from $23.00 to $28.00 and gave the company a "buy" rating in a research report on Monday. Leerink Partners lifted their price target on Cogent Biosciences from $16.00 to $18.00 and gave the company an "outperform" rating in a research note on Monday. Needham & Company LLC restated a "hold" rating on shares of Cogent Biosciences in a research note on Tuesday, June 17th. Guggenheim reaffirmed a "buy" rating and issued a $17.00 price target on shares of Cogent Biosciences in a report on Tuesday. Finally, Wedbush reaffirmed a "neutral" rating and issued a $10.00 price target on shares of Cogent Biosciences in a report on Monday, June 30th.

Get Our Latest Stock Report on COGT

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Strs Ohio purchased a new position in Cogent Biosciences in the first quarter worth $36,000. CWM LLC grew its position in Cogent Biosciences by 11,869.9% in the first quarter. CWM LLC now owns 8,738 shares of the technology company's stock worth $52,000 after acquiring an additional 8,665 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in Cogent Biosciences in the fourth quarter worth $78,000. Hsbc Holdings PLC purchased a new position in Cogent Biosciences in the fourth quarter worth $81,000. Finally, KLP Kapitalforvaltning AS purchased a new position in Cogent Biosciences in the fourth quarter worth $88,000.

Cogent Biosciences Trading Up 1.2%

NASDAQ:COGT traded up $0.13 on Tuesday, hitting $10.98. The company's stock had a trading volume of 3,386,326 shares, compared to its average volume of 1,570,620. The stock has a fifty day moving average of $6.54 and a two-hundred day moving average of $6.84. The firm has a market capitalization of $1.25 billion, a P/E ratio of -5.97 and a beta of 1.88. Cogent Biosciences has a one year low of $3.72 and a one year high of $12.61.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The technology company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.04. As a group, sell-side analysts anticipate that Cogent Biosciences will post -2.42 EPS for the current year.

Cogent Biosciences Company Profile

(Get Free Report

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

Further Reading

Analyst Recommendations for Cogent Biosciences (NASDAQ:COGT)

Should You Invest $1,000 in Cogent Biosciences Right Now?

Before you consider Cogent Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cogent Biosciences wasn't on the list.

While Cogent Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday
ACT FAST! Congress is Dumping these 3 Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines